Access Industries and Pharmstandard-backed immuno-oncology therapy developer Neon Therapeutics floated in the middle of its range.
US-based cancer drug developer Neon Therapeutics went public on Wednesday in a $100m initial public offering that scored exits for diversified conglomerate Access Industries and pharmaceutical firm Pharmstandard.
The offering consisted of 6.25 million shares issued on the Nasdaq Global Select Market priced at $16.00 each, in the middle of the IPO’s $15 to $17 range. The shares opened at $15.65 on Wednesday and closed at $13.48 last night.
Neon is developing immuno-oncology therapies meant to fight cancer by…
